| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Viemed Healthcare, Inc. Common Shares
$8.89
+0.07 (+0.79%)
Market Cap
338.41 M
EPS
0.38
P/E Ratio
23.36 $
Value Trade
6.69 M
-0.22 %
Week
-4.72 %
1 Month
-23.56 %
3 Month
-3.89 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
143.59 K
52 Week Range
6.05 - 12.61
% held by Insiders
13.93 %
% held by Institutions
74.4 %
Enterprise Value
335.40 M
Total Shares
38.10 M
Short %
4.04 %
Float Shares
32.78 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
No drug pipeline
Viemed Healthcare, Inc. Common Shares is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-VMD
Sep 24, 2026▲ +0.8%today
Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Viemed Healthcare, Inc. announced that President Michael Moore has adopted an Automatic Securities Disposition Plan (ASDP) for selling shares. This plan allows for predetermined sales of up to 246,000 common shares over a year, ensuring compliance with securities regulations. The ASDP aims to facilitate transparent trading while limiting insider discretion.
Read more →-VMD
Mar 5, 2026▼ -7.5%on this news
Viemed Healthcare Announces Record 2025 Financial Results
Viemed Healthcare reported record financial results for 2025, with net revenues reaching $270.3 million, a 21% increase from the previous year. The company also achieved a net income of $14.9 million, marking its ninth consecutive year of profitability. Looking ahead, Viemed anticipates continued growth in 2026, projecting revenues between $310 million and $320 million.
Read more →-VMD
Mar 4, 2026Document VIEMED HEALTHCARE ANNOUNCES 2026 SHARE REPURCHASE PROGRAM LAFAYETTE, La., (
Viemed Healthcare, Inc. has announced a share repurchase program effective through March 2027, allowing the company to buy back up to approximately 5% of its outstanding shares. This decision, authorized by the Board of Directors, reflects the company's confidence in its strong cash flows and balance sheet. In 2025, Viemed reported record revenue and significantly increased free cash flow, ending the year with minimal debt. This move is part of Viemed's broader capital allocation strategy alongside its ongoing investments in growth and acquisitions.
Read more →-VMD
Feb 24, 2026Viemed Healthcare Announces Year End 2025 Earnings Conference Call Details
Viemed Healthcare, Inc. has announced its Year End 2025 earnings conference call scheduled for March 5, 2026. The call will provide insights into the company's performance and future strategies. Interested participants can join via phone or through a live audio webcast. A replay will be available afterward on the company's website.
Read more →-VMD
Sep 23, 2025Document VIEMED HEALTHCARE ANNOUNCES COMPLETION OF SHARE REPURCHASE PROGRAM LAFAYETTE, La., (
Viemed Healthcare, Inc. has successfully completed its share repurchase program, buying back 1,976,441 shares for approximately $13.2 million. The initiative was authorized by the Board of Directors in June 2025, representing about 5% of the total shares outstanding. CEO Casey Hoyt emphasized that this move reflects the company's strong confidence in its future growth and commitment to enhancing shareholder value. The program was executed through compliant open market transactions.
Read more →-VMD
Jul 2, 2025Document VIEMED COMPLETES ACQUISITION OF LEHAN'S MEDICAL EQUIPMENT ANTICIPATES UPDATING ITS FULL YEAR 2025 OUTLOOK FOR THE ACQUISITION WITH SECOND QUARTER 2025 FINANCIAL RESULTS LAFAYETTE, Louisiana (
Viemed Healthcare, Inc. has successfully completed its acquisition of Lehan's Medical Equipment for $26 million, which may increase to $28.2 million with contingent payments. The acquisition will enable Viemed to leverage Lehan's extensive experience and brand recognition in the healthcare market, particularly in home medical equipment. With Lehan's reported revenues of approximately $25.7 million in 2024, Viemed expects to provide updated financial guidance for 2025 that reflects the anticipated contributions from this acquisition.
Read more →-VMD
Jun 9, 2025Document VIEMED HEALTHCARE ANNOUNCES SHARE REPURCHASE PROGRAM LAFAYETTE, La., (
Viemed Healthcare, Inc. has announced a share repurchase program authorized by its Board of Directors, allowing the purchase of up to 1,976,441 common shares through June 2026. This initiative reflects the company's strategic capital allocation, backed by strong first-quarter results and enhanced financial guidance. The company has previously repurchased approximately 2.6 million shares since its public listing and currently maintains a solid liquidity position with no net debt.
Read more →-VMD
May 6, 2025Document VIEMED EXECUTES DIVERSIFICATION STRATEGY WITH $26 MILLION ACQUISITION OF HOME EQUIPMENT PROVIDER IN ILLINOIS LAFAYETTE, Louisiana (
Viemed Healthcare, Inc. has announced the acquisition of Illinois-based Lehan's Medical Equipment for $26 million. This deal allows Viemed to diversify its product offerings into maternal health and respiratory care, leveraging Lehan's established market presence. The transaction is expected to close in the third quarter of 2025, pending customary adjustments. Viemed intends to fund the acquisition using a mix of cash and existing credit facilities.
Read more →-VMD
Apr 2, 2024▼ -5.8%on this news
Document VIEMED ANNOUNCES ACQUISITION OF MAJORITY INTEREST IN HOMEMED, FORGING PARTNERSHIP WITH EAST ALABAMA HEALTH Lafayette, Louisiana (
Viemed Healthcare, Inc. has finalized its acquisition of a majority interest in HomeMed, establishing a strategic partnership with East Alabama Health. This transaction, which closed on April 1, 2024, allows Viemed to take managerial control of HomeMed and is expected to contribute an incremental annualized revenue of about $4 million. The collaboration aims to enhance home medical services within the East Alabama region, aligning with both organizations' commitment to quality patient care. Viemed views this partnership as a model for future expansions nationwide.
Read more →-VMD
Dec 7, 2023Document VIEMED TO CENTRALIZE MARKET FOR COMMON SHARES ON NASDAQ THROUGH VOLUNTARY DELISTING FROM TSX Lafayette, Louisiana (
Viemed Healthcare, Inc. has announced its voluntary delisting from the Toronto Stock Exchange (TSX) to consolidate its market presence on NASDAQ. The delisting is intended to improve market efficiency and optimize administrative processes, as a significant portion of trading volume is already concentrated in the U.S. The delisting will take effect at the close of markets on December 21, 2023, with no negative impact on the existing NASDAQ listing, ensuring shareholders can still trade their shares effectively.
Read more →-VMD
Jun 1, 2023Document VIEMED ANNOUNCES SUCCESSFUL COMPLETION OF HMP ACQUISITION Lafayette, Louisiana (
Viemed Healthcare, Inc. has announced the successful completion of its acquisition of Home Medical Products, Inc. This acquisition, valued at approximately $28 million, positions Viemed to enhance its service offerings in respiratory care. With the integration of HMP, which serves around 45,000 active patients, Viemed anticipates a significant boost in net revenues for the second quarter of 2023. The leadership emphasizes the importance of synergy and quality patient care stemming from this merger.
Read more →-VMD
Apr 18, 2023Document VIEMED ACCELERATES GROWTH THROUGH ACQUISITION OF TENNESSEE BASED HOME MEDICAL PRODUCTS, INC. Lafayette, Louisiana (
Viemed Healthcare, Inc. has announced its acquisition of Tennessee-based Home Medical Products, Inc. (HMP), a provider of respiratory-focused home medical solutions. This strategic acquisition aims to enhance Viemed's growth trajectory, allowing both companies to combine their strengths in delivering patient-centered care. HMP reported net revenues of approximately $28 million in 2022 and is expected to close the acquisition by June 2023 at a purchase price of about $31.75 million, which will be funded through a mix of cash and borrowings. Key members of HMP's team will join Viemed post-acquisition, reinforcing their commitment to better healthcare solutions.
Read more →-VMD
Jan 23, 2023Document VIEMED WINS COMPLETE OVERRULING OF APPEALED OIG CLAIMS RESOLVING MULTIYEAR PROCESS WITH HHS AND CMS Lafayette, Louisiana (
Viemed Healthcare, Inc. has successfully won a complete overruling of appealed claims from the U.S. Department of Health and Human Services Office of Inspector General, as decided by a U.S. Administrative Law Judge. This decision resolved all remaining disputed claims of non-compliance, allowing Medicare Administrative Contractors to return all previously remitted funds to Viemed. The company views this outcome as a reaffirmation of its clinical protocols, ensuring that patients retain access to essential non-invasive ventilation care.
Read more →-VMD
Jan 12, 2023▲ +6.5%on this news
Document VIEMED ANNOUNCES STRATEGIC INVESTMENT IN POPULATION HEALTH SECTOR Lafayette, Louisiana (
Viemed Healthcare, Inc. has announced a $2 million strategic investment in ModoHealth, which focuses on value-based care and patient management. This partnership aims to expand ModoHealth's patient management network by leveraging data-driven solutions to enhance healthcare delivery. By participating in ModoHealth's platform, Viemed hopes to improve patient outcomes for those suffering from respiratory conditions such as COPD and sleep apnea. The deal includes receiving an 18-month secured convertible promissory note.
Read more →-VMD
Nov 29, 2022Document VIEMED ANNOUNCES NEW SENIOR SECURED CREDIT FACILITIES Lafayette, Louisiana (
VIEMED ANNOUNCES NEW SENIOR SECURED CREDIT FACILITIES Lafayette, Louisiana (November 29, 2022) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ VMD and TSX VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced
Read more →-VMD
Aug 1, 2022Document VIEMED ANNOUNCES EXECUTIVE ADDITIONS TO LEAD ACQUISITION GROWTH Lafayette, Louisiana (
VIEMED ANNOUNCES EXECUTIVE ADDITIONS TO LEAD ACQUISITION GROWTH Lafayette, Louisiana (August 1, 2022) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ VMD and TSX VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, an
Read more →-VMD
Jul 5, 2022Document VIEMED ANNOUNCES PUBLICATION OF PEER-REVIEWED NIVH STUDY FINDING TREATMENT REDUCES HEALTHCARE COSTS AND SAVES LIVES Lafayette, Louisiana (
VIEMED ANNOUNCES PUBLICATION OF PEER-REVIEWED NIVH STUDY FINDING TREATMENT REDUCES HEALTHCARE COSTS AND SAVES LIVES Lafayette, Louisiana (July 5, 2022) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ VMD and TSX VMD.TO), a national leader in respiratory care and tec
Read more →-VMD
May 16, 2022▲ +5%on this news
Document VIEMED PROVIDES UPDATE CONCERNING SUCCESSFUL APPEAL OF OFFICE OF INSPECTOR GENERAL FINDINGS Lafayette, Louisiana (
VIEMED PROVIDES UPDATE CONCERNING SUCCESSFUL APPEAL OF OFFICE OF INSPECTOR GENERAL FINDINGS Lafayette, Louisiana (May 16, 2022) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ VMD and TSX VMD.TO), a home medical equipment supplier and the nation's largest independent
Read more →-VMD
May 24, 2021Document VIEMED HEALTHCARE COMMENTS ON FINAL REPORT ISSUED BY OFFICE OF INSPECTOR GENERAL Lafayette, Louisiana (
VIEMED HEALTHCARE COMMENTS ON FINAL REPORT ISSUED BY OFFICE OF INSPECTOR GENERAL Lafayette, Louisiana (May 24, 2021) Viemed Healthcare, Inc. (the "Company" or "Viemed") (TSX VMD.TO and NASDAQ VMD), a home medical equipment supplier and the nation's largest independent provider o
Read more →-VMD
May 6, 2020informationcircular NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2020 AND MANAGEMENT INFORMATION CIRCULAR VIEMED HEALTHCARE, INC. NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS NOTICE IS
NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2020 AND MANAGEMENT INFORMATION CIRCULAR VIEMED HEALTHCARE, INC. NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual and special meeting (the "Meeting") of shareholder
Read more →-VMD
Aug 9, 2019VIEMED HEALTHCARE ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2019 Lafayette, Louisiana (
VIEMED HEALTHCARE ANNOUNCES FINANCIAL RESULTS FOR Lafayette, Louisiana (August 9, 2019) Viemed Healthcare, Inc. (the "Company" or "Viemed") (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, a
Read more →Competitive Position
How VMD ranks across every disease it competes inCompetitive Position is a premium feature
See how VMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial